Situation of imipenem in the treatment of obstretic and gynecological infections at the National Hospital of Obstetrics and Gynecology in 2022 - 2023

Abstract

Imipenem, one of reserve antibiotics, is in high demand for use at the National Hospital of Obstetrics and Gynecology. The objective of this study is to describe the situation of imipenem use in the Division of Obstetric and Gynecological Infections, National Hospital of Obstetrics and Gynecology. A prospective descriptive study was conducted on 55 medical records using Imipenem in the Division of Obstetric and Gynecological Infections in the period of 9/2022 - 3/2023. The research results showed that 54 patients were diagnosed with an infection. The most common bacterial infection was tubo-ovarian abscess (46.4%) and postoperative abdominal wound infection (21.4%). Microbilogical tests were indicated for all patients with a diagnosis of bacterial infection. Almost Gram-negative bacteria were sensitive to imipenem (93%). Imipenem was mostly used in empirical therapy (83.3%). The imipenem combination regimen accounted for 62.5%, of which levofloxacin was the most commonly combined antibiotic. Imipenem was prescribed with a common dose regimen of 1g, 2 - 3 times per day (83.7%). The majority (74.5%) of dosing intervals were nonequidistant. In conclusion, although imipenem was indicated for the reported infections in the study, imipenem use was not optimal in some cases. There is a need to develop guidelines for the treatment of obstetric and gynecological infections based on the optimal use of imipenem.